diphenhydramine + lorazepam + dexamethasone

A combination antiemetic therapy consisting of diphenhydramine, lorazepam, and dexamethasone, developed by the University of South Florida for the treatment of chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. Administered via a continuous infusion pump (the 'BAD pump'), the regimen combines an antihistamine, a benzodiazepine, and a corticosteroid to provide both continuous and on-demand relief. Diphenhydramine acts as a histamine H1 receptor antagonist, lorazepam as a GABA-A receptor positive allosteric modulator, and dexamethasone as a glucocorticoid receptor agonist. This multi-targeted approach aims to improve emetic control compared to standard therapies like ondansetron in children receiving moderately or highly emetogenic chemotherapy.

Other names

BAD regimenBAD combination